Beijing Zhuokai Biotechnology

Beijing Zhuokai Biotechnology is a Chinese biopharmaceutical company specializing in the development of next-generation gene therapies. The company leverages its proprietary Adeno-Associated Virus (AAV) vector platform and gene-editing technologies to create treatments for rare diseases, particularly in the fields of ophthalmology and neurology. Its lead candidate, ZK-001, is an AAV-based gene therapy targeting Leber Congenital Amaurosis caused by RPE65 mutations. Founded in 2021 by Dr. Zhang Kai, the company is headquartered in Beijing's Zhongguancun Life Science Park. Zhuokai has successfully raised significant funding from top-tier venture capital firms like Legend Capital and GL Ventures to advance its pipeline. The company's mission is to provide curative solutions for patients with severe genetic disorders through innovative genetic medicine.